ERBB2 and breast carcinoma: Advancements in anti-HER2 therapies, beginning with trastuzumab and moving beyond with agents like Trastuzumab emtansine, Trastuzumab deruxtecan, tucatinib, Margetuximab, neratinib, etc., have significantly improved outcomes for HER2-positive breast cancer patients [6].